Aktionärsstruktur

Inhaber in %
Freefloat 99,91
Vanguard Group, Inc. (Subfiler) 8,11
The Vanguard Group, Inc. 7,90
Wellington Management Co. LLP 6,73
State Street Corp. 4,21
Wellington Management Co. LLP 3,56
Dodge & Cox 3,10
Vanguard Health Care Fund 3,08
Vanguard Total Stock Market Index Fund 2,82
BlackRock Institutional Trust Co. NA 2,56
Fidelity Management & Research Co. LLC 2,48
BlackRock Fund Advisors 2,18
Renaissance Technologies LLC 2,01
Vanguard 500 Index Fund 1,99
Dodge & Cox Funds - Stock Fund 1,87

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2015 2016 2017 2018 2019
Personal am Ende des Jahres 25.000 25.000 23.700 23.300 30.000
Umsatz pro Mitarbeiter in Mio. EUR 0,66 0,78 0,88 0,97 0,87

Bilanz (in Mio. EUR) - Aktiva

2015 2016 2017 2018 2019
Summe Umlaufvermögen 10.415 13.704 14.854 17.160 29.354
Summe Anlagevermögen 20.955 22.885 19.703 21.380 99.136
Summe Aktiva 31.748 33.707 33.551 34.986 129.944

Bilanz (in Mio. EUR) - Passiva

2015 2016 2017 2018 2019
Gesamtverschuldung/ -verbindlichkeiten 6.689 6.708 7.962 7.349 47.538
Summe Fremdkapital 17.324 17.360 21.704 20.859 78.246
Summe Eigenkapital 14.424 16.347 11.847 14.127 51.698
Summe Passiva 31.748 33.707 33.551 34.986 129.944

Adresse

430 East 29th Street, 10016 New York
Telefon +1 (212) 546-4000
Internet http://www.bms.com

Management

Adam Dubow
Senior VP, Chief Compliance & Ethics Officer
Ann Powell Judge
Chief Human Resources Officer & Senior VP
Christopher S. Boerner
Chief Commercial Officer & Executive VP
Daniel O'Connell
Executive Director-Corporate Development
David V. Elkins
Chief Financial Officer & Executive Vice President
Dinesh C Paliwal
Independent Director
Elizabeth Mily
Executive VP-Strategy & Business Development
Fouad Namouni
Head-Oncology Development
Gerald L. Storch
Independent Director
Giovanni Caforio
Chairman & Chief Executive Officer
Julia A. Haller
Director
Karen H. Vousden
Independent Director
Karen Murphy Santiago
Senior Vice President & Corporate Controller
Katherine Reynolds Kelly
Secretary & Vice President
Kristen M. Hege
SVP-Clinical Development & Cell Therapy
Laura Hortas
Head-Corporate & Employee Communications
Louis S. Schmukler
President-Global Product Development & Supply
Matthew W. Emmens
Independent Director
Michael W. Bonney
Director
Paul von Autenried
Chief Information Officer & Senior Vice President
Peter J. Arduini
Independent Director
Phyllis R. Yale
Director
Robert J. Bertolini
Independent Director
Rupert J. Vessey
President-Research & Early Development
Sabine Maier
Executive Director & Clinical Team Lead
Samit Hirawat
Chief Medical Officer-Global Drug Development
Sandra Leung
Executive Vice President & General Counsel
Saurabh Saha
Senior Vice P & Head-Translational Medicine
Theodore Rapp Samuels
Independent Director
Tim Power
Head-Investor Relations
Vicki L. Sato
Lead Independent Director